한글목차

세계의 의약품 임상시험수탁기관(CRO) 시장 규모는 2033년까지 10.6%의 CAGR로 성장할 것으로 예측됩니다.

바이오의약품 시장은 성장세를 보이고 있습니다. 고령화로 인한 헬스케어 수요 증가로 인해 이를 충족시키기 위해 생명공학, 제약, 의료기기 산업이 확대되고 있습니다. 이에 따라 제품의 유효성과 안전성을 보장하기 위한 효과적인 임상시험에 대한 수요도 증가하고 있습니다. 전 세계적으로 약 26만 6,000건의 공개 임상시험이 진행 중입니다. 미국에서만 현재 10만 5,000건 이상의 공개 임상시험이 진행되고 있습니다.

전 세계적으로 희귀질환의 부담이 증가하고 있으며, 이는 의약품의 증가와 혁신으로 이어지고 있습니다. 매년 말기 희귀질환 환자 중 극히 일부만이 초기 치료를 받을 수 있으며, 이들 중 90% 이상은 치료제 승인을 기다리고 있습니다. CDC에 따르면, 2021년에는 전 세계 인구의 약 10%에 해당하는 4억 7,500만 명이 희귀질환을 앓고 있는 것으로 추정됩니다. 향후 5년간 1,520만 명이 희귀질환에 대한 임상유전자 검사를 받을 것으로 예측됩니다. 또한, 희귀질환 환자들을 지원하는 정부 프로그램을 도입하는 국가들이 늘어나고 있습니다.

세계의 의약품 임상시험수탁기관(CRO) 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추정과 예측, 각종 부문·지역/주요 국가별 내역, 경쟁 환경, 주요 기업 개요 등을 정리했습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter's Five Forces 분석
• SWOT 분석
• PEST 분석
• 제약 업계는 팬데믹 상황에서 어떻게 적응해 왔는가?
• CRO가 M&A를 채용하는 이유는?

제4장 의약품 임상시험수탁기관(CRO) 시장 분석 : 서비스별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 전임상
• 임상
  • 단계 I
  • 단계 II
  • 단계Ⅲ
  • 단계 IV
• 실험실 서비스
• 컨설팅 서비스
• 데이터 관리 서비스

제5장 의약품 임상시험수탁기관(CRO) 시장 분석 : 기업 규모별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 대규모 기업
• 중규모
• 소규모

제6장 의약품 임상시험수탁기관(CRO) 시장 분석 : 의약품 유형별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 저분자
• 고분자

제7장 의약품 임상시험수탁기관(CRO) 시장 분석 : 치료 분야별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추정과 예측
• 종양
• 중추신경계
• 심장병
• 감염성
• 대사
• 기타

제8장 의약품 임상시험수탁기관(CRO) 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추정과 예측

제9장 북미의 의약품 임상시험수탁기관(CRO) 시장 분석

제10장 유럽의 의약품 임상시험수탁기관(CRO) 시장 분석

제11장 아시아태평양의 의약품 임상시험수탁기관(CRO) 시장 분석

제12장 라틴아메리카의 의약품 임상시험수탁기관(CRO) 시장 분석

제13장 중동 및 아프리카의 의약품 임상시험수탁기관(CRO) 시장 분석

제14장 기업 개요

• 경쟁 상황
• Charles River Laboratories
• CMIC HOLDINGS Co., Ltd.
• Caidya
• ICON plc
• IQVIA Inc.
• Labcorp Drug Development
• Medpace
• Parexel International(MA) Corporation
• Thermo Fisher Scientific Inc.(PPD)
• Syneos Health
• Worldwide Clinical Trials
• Wuxi AppTec
• Eurofins Scientific
• Evotec SE
• Allucent
• Syngene International
• Anthem Biosciences Private Limited
• The Emmes Company, LLC
• Bio-Techne
• Inotiv
• Frontage Labs.

제15장 결론과 제안

영문목차

The global Contract Research Organisations (CROs) market is projected to grow at a CAGR of 10.6% by 2033.

“The Contract Research Organisations (CROs) Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The market for biopharmaceuticals is rising, there is an increase in the need for healthcare due to an ageing population, and the biotech, pharmaceutical, and medical device industries are expanding to fulfil this demand. As a result, the demand for effective clinical studies has increased in order to ensure the efficacy and safety of products. Worldwide, there are around 266 thousand open clinical trials ongoing. More than 105,000 open clinical investigations are now being conducted just in the United States.

The burden of uncommon diseases is increasing internationally, which has led to an increase and innovation in the creation of medicines. While it is still true that only a small portion of terminal rare diseases receive their initial treatment each year and that over 90% of these diseases await therapy approval. In 2021, the CDC reported that 475 million individuals, or nearly 10% of the world's population, were thought to be living with a rare disease. 15.2 million Individuals are predicted to receive clinical genetic testing for a rare disease during the course of the next five years. A rising number of nations are putting in place government programs to assist people with rare illnesses.

Intellectual Property Issues Likely to Challenge Industry Growth

Intellectual property is one of the key barriers to outsourcing clinical trials, which might restrict the expansion of contract research organisations' markets. Because copyrighted products make up the majority of therapeutic candidates, a contract research organisation may increase the danger of data leaks.

Additionally, pharmaceutical companies that develop novel medicines are expected to provide clinical data about safety and efficacy to the relevant governmental and regulatory bodies in order for their treatments to be approved. As a result, the guidelines for pre- and post-grant disagreement as well as issues pertaining to the patent are quite strict. However, it improves the efficiency of inspection and has assisted in the cancellation of patents. It is crucial to focus more emphasis on clinical trial agreements since the government thoroughly evaluates clinical trial-related issues as well. However, these issues harm the CRO's reputation and may stop the sector for contract research organisations from expanding.

What Questions Should You Ask Before Buying a Market Research Report?

• How is the contract research organisations (CROs) market evolving?
• What is driving and restraining the contract research organisations (CROs) market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each contract research organisations (CROs) submarket develop from 2022 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading contract research organisations (CROs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the contract research organisations (CROs) projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of contract research organisations (CROs) projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the contract research organisations (CROs) market?
• Where is the contract research organisations (CROs) market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Contract Research Organisations (CROs) market today, and over the next 10 years:

• Our 353-page report provides 141 tables, 201 charts, and graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Contract Research Organisations (CROs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Research Organisations (CROs) prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Service

• Preclinical

• Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

• Laboratory Services
• Consulting Services
• Data Management Services

Company Size

• Large Pharma & Biotech Companies
• Mid-sized Pharma & Biotech Companies
• Small Pharma & Biotech Companies

Drug Type

• Small Molecules
• Large Molecules

Therapeutic Area

• Oncology
• CNS
• Cardiology
• Infectious
• Metabolic
• Other Therapeutic Area

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Switzerland
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Egypt
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Contract Research Organisations (CROs) Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Contract Research Organisations (CROs) Market, 2023 to 2033 in terms of value the market will surpass US$68 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Contract Research Organisations (CROs) Market, 2023 to 2033 report help you?

In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Contract Research Organisations (CROs) Market, 2023 to 2033, with forecasts for services, company size, drug type, and therapeutic area, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 25 key national markets - See forecasts for the Contract Research Organisations (CROs) Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, Argentina, GCC, South Africa, and Egypt among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 21 of the major companies involved in the Contract Research Organisations (CROs) Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Contract Research Organisations (CROs) Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Contract Research Organisations (CROs) Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Reports
• 1.10 About

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Rising Demand for Clinical Trials Globally
    • 3.2.1.2 Growing Disease Burden Globally to Fuel CROs Market Growth
    • 3.2.1.3 Rising R&D Investments by Pharmaceutical and Biotech Companies to Boost CROs Market Growth
    • 3.2.1.4 Patent Expiry and Increasing Demand for Generic Drugs Projected to Drive Overall CROs Growth
    • 3.2.1.5 High Cost of In-house Drug Development
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Intellectual Property Issues May Hamper CROs Industry Growth
    • 3.2.2.2 Shortage of Skilled Labour Post COVID-19 Hampering CRO Industry
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Applications of Artificial Intelligence Could Lead to Faster, Safer and Significantly Less Expensive Clinical Trials
    • 3.2.3.2 Increasing Demand for Biological Therapies to Offer Lucrative Growth Prospects for CROs
    • 3.2.3.3 Growth in Nuclear Medicine Sector
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Competitive Rivalry: High
  • 3.4.2 Threat of New Entrants: Low to Medium
  • 3.4.3 Threat of Substitutes: Low to Medium
  • 3.4.4 Bargaining Power of Buyers: Medium to High
  • 3.4.5 Bargaining Power of Suppliers: Medium to High
• 3.5 SWOT Analysis
• 3.6 PEST Analysis
• 3.7 How has the Pharmaceutical Industry Adapted Amidst the Pandemic?
• 3.8 Why are CROs Adopting Mergers & Acquisitions?

4 Contract Research Organisations (CROs) Market Analysis by Services

• 4.1 Key Findings
• 4.2 Services Segment: Market Attractiveness Index
• 4.3 Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 4.4 Preclinical
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Clinical
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5.3 Phase I
    • 4.5.3.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.5.3.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5.4 Phase II
    • 4.5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5.5 Phase III
    • 4.5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5.6 Phase IV
    • 4.5.6.1 Market Size by Region, 2023-2033 (US$ Billion)
    • 4.5.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Laboratory Services
  • 4.6.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.7 Consulting Services
  • 4.7.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.7.2 Market Share by Region, 2023 & 2033 (%)
• 4.8 Data Management Services
  • 4.8.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Contract Research Organisations (CROs) Market, by Company Size, 2023-2033

• 5.1 Key Findings
• 5.2 Company Size Segment: Market Attractiveness Index
• 5.3 Contract Research Organisations (CROs) Market, by Company Size
• 5.4 Large Pharma & Biotech Companies
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Mid-sized Pharma & Biotech Companies
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Small Pharma & Biotech Companies
  • 5.6.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Contract Research Organisations (CROs) Market, by Drug Type, 2023-2033

• 6.1 Key Findings
• 6.2 Drug Type Segment: Market Attractiveness Index
• 6.3 Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 6.4 Small Molecules
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Large Molecules
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)

7 Contract Research Organisations (CROs) Market, by Therapeutic Area, 2023-2033

• 7.1 Key Findings
• 7.2 Therapeutic Area Segment: Market Attractiveness Index
• 7.3 Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 7.4 Oncology
  • 7.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.4.2 Market Share by Region, 2023 & 2033 (%)
• 7.5 CNS
  • 7.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.5.2 Market Share by Region, 2023 & 2033 (%)
• 7.6 Cardiology
  • 7.6.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.6.2 Market Share by Region, 2023 & 2033 (%)
• 7.7 Infectious
  • 7.7.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.7.2 Market Share by Region, 2023 & 2033 (%)
• 7.8 Metabolic
  • 7.8.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.8.2 Market Share by Region, 2023 & 2033 (%)
• 7.9 Other Therapeutic Area
  • 7.9.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 7.9.2 Market Share by Region, 2023 & 2033 (%)

8 Contract Research Organisations (CROs) Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Contract Research Organisations (CROs) Market Analysis

• 9.1 Key Findings
• 9.2 North America Contract Research Organisations (CROs) Market Attractiveness Index
• 9.3 North America Contract Research Organisations (CROs) Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 9.4 North America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Country
• 9.5 North America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 9.6 North America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Company Size
• 9.7 North America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 9.8 North America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 9.9 U.S. Contract Research Organisations (CROs) Market Analysis
• 9.10 Canada Contract Research Organisations (CROs) Market Analysis

10 Europe Contract Research Organisations (CROs) Market, 2023-2033

• 10.1 Key Findings
• 10.2 Europe Contract Research Organisations (CROs) Market Attractiveness Index
• 10.3 Europe Contract Research Organisations (CROs) Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 10.4 Europe Contract Research Organisations (CROs) Market Size Estimation and Forecast by Country
• 10.5 Europe Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 10.6 Europe Contract Research Organisations (CROs) Market Size Estimation and Forecast by Company Size
• 10.7 Europe Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 10.8 Europe Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 10.9 Germany Contract Research Organisations (CROs) Market Analysis
• 10.10 UK Contract Research Organisations (CROs) Market Analysis
• 10.11 France Contract Research Organisations (CROs) Market Analysis
• 10.12 Italy Contract Research Organisations (CROs) Market Analysis
• 10.13 Spain Contract Research Organisations (CROs) Market Analysis
• 10.14 Switzerland Contract Research Organisations (CROs) Market Analysis
• 10.15 Netherlands Contract Research Organisations (CROs) Market Analysis
• 10.16 Rest of Europe Contract Research Organisations (CROs) Market Analysis

11 Asia Pacific Contract Research Organisations (CROs) Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Contract Research Organisations (CROs) Market Attractiveness Index
• 11.3 Asia Pacific Contract Research Organisations (CROs) Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 11.4 Asia Pacific Contract Research Organisations (CROs) Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 11.6 Asia Pacific Contract Research Organisations (CROs) Market Size Estimation and Forecast by Company Size
• 11.7 Asia Pacific Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 11.8 Asia Pacific Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 11.9 Japan Contract Research Organisations (CROs) Market Analysis
• 11.10 China Contract Research Organisations (CROs) Market Analysis
• 11.11 India Contract Research Organisations (CROs) Market Analysis
• 11.12 Australia Contract Research Organisations (CROs) Market Analysis
• 11.13 South Korea Contract Research Organisations (CROs) Market Analysis
• 11.14 Singapore Contract Research Organisations (CROs) Market Analysis
• 11.15 Rest of Asia Pacific Contract Research Organisations (CROs) Market Analysis

12 Latin America Contract Research Organisations (CROs) Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Contract Research Organisations (CROs) Market Attractiveness Index
• 12.3 Latin America Contract Research Organisations (CROs) Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 12.4 Latin America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Country
• 12.5 Latin America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 12.6 Latin America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Company Size
• 12.7 Latin America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 12.8 Latin America Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 12.9 Brazil Contract Research Organisations (CROs) Market Analysis
• 12.10 Mexico Contract Research Organisations (CROs) Market Analysis
• 12.11 Argentina Contract Research Organisations (CROs) Market Analysis
• 12.12 Rest of Latin America Contract Research Organisations (CROs) Market Analysis

13 MEA Contract Research Organisations (CROs) Market Analysis

• 13.1 Key Findings
• 13.2 MEA Contract Research Organisations (CROs) Market Attractiveness Index
• 13.3 MEA Contract Research Organisations (CROs) Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 13.4 MEA Contract Research Organisations (CROs) Market Size Estimation and Forecast by Country
• 13.5 MEA Contract Research Organisations (CROs) Market Size Estimation and Forecast by Services
• 13.6 MEA Contract Research Organisations (CROs) Market Size Estimation and Forecast by Company Size
• 13.7 MEA Contract Research Organisations (CROs) Market Size Estimation and Forecast by Drug Type
• 13.8 MEA Contract Research Organisations (CROs) Market Size Estimation and Forecast by Therapeutic Area
• 13.9 GCC Contract Research Organisations (CROs) Market Analysis
• 13.10 South Africa Contract Research Organisations (CROs) Market Analysis
• 13.11 Egypt Contract Research Organisations (CROs) Market Analysis
• 13.12 Rest of MEA Contract Research Organisations (CROs) Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2022
• 14.2 Charles River Laboratories
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2018-2022
    • 14.2.3.2 Segment Market Shares, 2022
    • 14.2.3.3 Regional Market Shares, 2022
  • 14.2.4 Service Benchmarking
  • 14.2.5 Strategic Outlook
• 14.3 CMIC HOLDINGS Co., Ltd.
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2018-2022
    • 14.3.3.2 Segment Market Shares, 2022
  • 14.3.4 Service Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Caidya
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Service Benchmarking
  • 14.4.4 Strategic Outlook
• 14.5 ICON plc
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2018-2022
    • 14.5.3.2 Regional Market Shares, 2022
  • 14.5.4 Service Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 IQVIA Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2018-2022
    • 14.6.3.2 Segment Market Shares, 2022
    • 14.6.3.3 Regional Market Shares, 2022
  • 14.6.4 Service Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Labcorp Drug Development
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Net Revenue, 2018-2022
    • 14.7.3.2 Segment Market Shares, 2022
    • 14.7.3.3 Regional Market Shares, 2022
  • 14.7.4 Service Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 Medpace
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Net Revenue, 2018-2022
    • 14.8.3.2 Segment Market Shares, 2022
  • 14.8.4 Service Benchmarking
• 14.9 Parexel International (MA) Corporation
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Service Benchmarking
  • 14.9.4 Strategic Outlook
• 14.10 Thermo Fisher Scientific Inc. (PPD)
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Net Revenue, 2018-2022
    • 14.10.3.2 R&D, 2018-2022
    • 14.10.3.3 Segment Market Shares, 2022
    • 14.10.3.4 Regional Market Shares, 2022
  • 14.10.4 Service Benchmarking
  • 14.10.5 Strategic Outlook
• 14.11 Syneos Health
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2018-2022
    • 14.11.3.2 Segment Market Shares, 2022
    • 14.11.3.3 Regional Market Shares, 2022
  • 14.11.4 Service Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 Worldwide Clinical Trials
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Service Benchmarking
  • 14.12.4 Strategic Outlook
• 14.13 Wuxi AppTec
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Net Revenue, 2018-2022
    • 14.13.3.2 Segment Market Shares, 2022
    • 14.13.3.3 Regional Market Shares, 2022
  • 14.13.4 Service Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 Eurofins Scientific
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Net Revenue, 2018-2022
    • 14.14.3.2 Segment Market Shares, 2022
    • 14.14.3.3 Regional Market Shares, 2022
  • 14.14.4 Service Benchmarking
  • 14.14.5 Strategic Outlook
• 14.15 Evotec SE
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Net Revenue, 2018-2022
    • 14.15.3.2 R&D, 2018-2022
    • 14.15.3.3 Regional Market Shares, 2022
  • 14.15.4 Service Benchmarking
  • 14.15.5 Strategic Outlook
• 14.16 Allucent
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Service Benchmarking
  • 14.16.4 Strategic Outlook
• 14.17 Syngene International
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Financial Analysis
    • 14.17.3.1 Net Revenue, 2018-2022
    • 14.17.3.2 Regional Market Shares, 2022
  • 14.17.4 Service Benchmarking
  • 14.17.5 Strategic Outlook
• 14.18 Anthem Biosciences Private Limited
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Service Benchmarking
• 14.19 The Emmes Company, LLC
  • 14.19.1 Company Snapshot
  • 14.19.2 Company Overview
  • 14.19.3 Service Benchmarking
  • 14.19.4 Strategic Outlook
• 14.20 Bio-Techne
  • 14.20.1 Company Snapshot
  • 14.20.2 Company Overview
  • 14.20.3 Financial Analysis
    • 14.20.3.1 Net Revenue, 2018-2022
    • 14.20.3.2 R&D, 2018-2022
    • 14.20.3.3 Segment Market Shares, 2022
    • 14.20.3.4 Regional Market Shares, 2022
  • 14.20.4 Service Benchmarking
  • 14.20.5 Strategic Outlook
• 14.21 Inotiv
  • 14.21.1 Company Snapshot
  • 14.21.2 Company Overview
  • 14.21.3 Financial Analysis
    • 14.21.3.1 Net Revenue, 2018-2022
    • 14.21.3.2 Segment Market Shares, 2022
    • 14.21.3.3 Regional Market Shares, 2022
  • 14.21.4 Service Benchmarking
  • 14.21.5 Strategic Outlook
• 14.22 Frontage Labs.
  • 14.22.1 Company Snapshot
  • 14.22.2 Company Overview
  • 14.22.3 Financial Analysis
    • 14.22.3.1 Net Revenue, 2018-2022
    • 14.22.3.2 R & D, 2018-2022
    • 14.22.3.3 Segment Market Shares, 2022
    • 14.22.3.4 Regional Market Shares, 2022
  • 14.22.4 Service Benchmarking
  • 14.22.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from
• 15.2 Recommendations for Market Players